AlloVir does not control and is not responsible for the content on the website you are about to visit. AlloVir is providing this link as a convenience, and this link does not imply AlloVir’s endorsement of any material on the website you are about to visit. Do you wish to continue?
Our allogeneic, virus-specific T cell (VST) therapy candidates target 11 different devastating viruses as treatment or prevention.
Our proprietary platform develops off-the-shelf VSTs that restore immunity in patients with T cell deficiencies.
Meet the team
We have a singular vision: to create T cell therapies that serve patients at risk of the devastating consequences of severe viral diseases.